2017
Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713
Leichman CG, McDonough SL, Smalley SR, Billingsley KG, Lenz HJ, Beldner MA, Hezel AF, Velasco MR, Guthrie KA, Blanke CD, Hochster HS. Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713. Clinical Colorectal Cancer 2017, 17: e121-e125. PMID: 29233486, PMCID: PMC6598683, DOI: 10.1016/j.clcc.2017.10.008.Peer-Reviewed Original ResearchConceptsPathologic complete responseAdvanced rectal cancerNeoadjuvant chemoradiationRectal cancerInduction chemotherapyKRAS wild-type metastatic colorectal cancerWild-type metastatic colorectal cancerThree-year disease-free survivalLocally Advanced Rectal CancerMetastatic colorectal cancerDisease-free survivalPhase III trialsAdequate hematologicEligible patientsBowel obstructionSame regimenIII trialsPerformance statusRenal functionComplete responseImproved survivalClinical outcomesMicroscopic cancerRectal adenocarcinomaPatient eligibility
2011
S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma
Leichman L, Goldman B, Bohanes P, Lenz H, Thomas C, Billingsley K, Corless C, Iqbal S, Gold P, Benedetti J, Danenberg K, Blanke C. S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma. Journal Of Clinical Oncology 2011, 29: 4555-4560. PMID: 22025151, PMCID: PMC3236655, DOI: 10.1200/jco.2011.36.7490.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalDrug Administration ScheduleEsophageal NeoplasmsEsophagectomyFemaleFluorouracilHumansMaleMiddle AgedNeoadjuvant TherapyOrganoplatinum CompoundsOxaliplatinRadiotherapy, AdjuvantConceptsPathologic complete responseEsophageal adenocarcinomaOverall survivalNeoadjuvant therapyExternal beam radiation therapyPhase II ClinicalProspective exploratory analysisPatient underwent surgeryPrimary end pointProgression-free survivalSouthwest Oncology GroupAdvanced esophageal adenocarcinomaSingle-arm trialGy/dNeoadjuvant oxaliplatinSystemic regimenPreoperative therapyR0 resectionUnderwent surgeryOncology GroupPCR rateComplete responseImproved survivalFuture trialsGrade 3